The osteogenic transcription factor Runx2 plays an important role in VSMC calcification in vitro. 4, 6, 7 Runx2 belongs to the runt-related transcription factor family and is essential for osteoblast differentiation and chondrocyte maturation. 8, 9 Multiple signals converge on the Runx2 transcription factor to regulate osteoblast differentiation. 10 -12 In normal vascular cells, the expression of Runx2 is very low, but Runx2 expression is elevated in calcified vascular tissue specimens from atherosclerotic plaque, suggesting that Runx2 may be important in vascular calcification. 13, 14 Using small interfering RNA, we have demonstrated that Runx2 is necessary for oxidative stress-induced VSMC calcification; and Runx2 by itself is sufficient to induce VSMC calcification in vitro. 7 However, the function of Runx2 in regulating vascular calcification in vivo is unknown. 
T he extent of vascular calcification, featuring calcium deposition-reduced elasticity, and decreased compliance of the vessel wall-predicts the cardiovascular outcome of atherosclerotic patients. Many studies have now supported the concept that vascular calcification is an active cell-driven process characterized by osteogenic differentiation of vascular cells. The origin of these cells has not been well defined. A variety of vascular cells-including vascular smooth muscle cells (VSMC), myofibroblasts, vascular mesenchymal progenitors, and endothelial cells-has been implicated in vascular calcification. [1] [2] [3] [4] [5] It is not clear to what extent transdifferentiation of VSMC contributes to the pathogenesis of vascular calcification in vivo, although many in vitro studies have demonstrated that VSMC can undergo osteogenic differentiation and calcification.
The osteogenic transcription factor Runx2 plays an important role in VSMC calcification in vitro. 4, 6, 7 Runx2 belongs to the runt-related transcription factor family and is essential for osteoblast differentiation and chondrocyte maturation. 8, 9 Multiple signals converge on the Runx2 transcription factor to regulate osteoblast differentiation. 10 -12 In normal vascular cells, the expression of Runx2 is very low, but Runx2 expression is elevated in calcified vascular tissue specimens from atherosclerotic plaque, suggesting that Runx2 may be important in vascular calcification. 13, 14 Using small interfering RNA, we have demonstrated that Runx2 is necessary for oxidative stress-induced VSMC calcification; and Runx2 by itself is sufficient to induce VSMC calcification in vitro. 7 However, the function of Runx2 in regulating vascular calcification in vivo is unknown.
Gene ablation of Runx2 in mice completely blocks bone formation and results in neonatal lethality, 8, 9 which precludes further characterization of the role of Runx2 in regulating vascular calcification in vivo. Therefore, generating a mouse model with vascular cell-specific Runx2 deficiency is necessary. The SM22␣-Cre transgenic mice have been shown to mediate specific and efficient recombination in the smooth muscle cell lineage 15 at E8.0 during embryonic development. 16 The C-terminus of Runx2 encoded by the exon 8 is critical for Runx2 function. 17 Truncation of the Runx2 exon 8 results in complete absence of bone formation and embryonic lethality, a phenotype similar to those observed in Runx2 null mutant mice. 18 The SMC-specific Runx2-deficient mouse model, generated by breeding SM22␣-Cre mice with the Runx2 exon 8 floxed mice, is an ideal model to determine the role of SMC-derived Runx2 in regulating vascular calcification in vivo.
Mice lacking apolipoprotein E (ApoE), a ligand for receptors that clear the remnants of chylomicrons and very-lowdensity lipoproteins, have been used as a valuable model to investigate the genetic and environmental factors that regulate pathogenesis of atherosclerotic vascular calcification. 19 -21 Using the ApoE Ϫ/Ϫ model, we have demonstrated that high-fat diet (HFD) induces Runx2 expression in the calcified atherosclerotic lesions, which is associated with increased macrophage infiltration and the presence of osteoclast-like cells in the vicinity of these lesions. 22 Monocyte/macrophage infiltration plays a critical role in the pathogenesis of atherosclerosis. 23, 24 Utilizing an in vitro coculture system of VSMC and macrophage, we have determined that increased Runx2 expression in VSMC upregulates the expression of ligand for receptor activator of nuclear factor B (RANKL), which promotes macrophage migration and formation of tartrate-resistant acid phosphatase (TRAP)-positive osteoclast-like cells. 22 However, the function of increased Runx2 production in the calcification of VSMC in vivo and SMC-derived Runx2 in regulating macrophage infiltration and the formation of osteoclast-like cells in the calcified atherosclerotic lesions remain unknown. In the present report, we have generated SMC-specific Runx2-deficient mice in the ApoE Ϫ/Ϫ background, and characterized the functional contribution of SMC-expressed Runx2 to the development of vascular calcification and macrophage infiltration in vivo.
We have determined that deletion of the Runx2 exon 8 in SMC inhibits vascular calcification in vivo, and concurrently blocks the upregulation of RANKL, macrophage infiltration and the formation of osteoclast-like cells in the atherosclerotic lesions. These data have demonstrated the importance of SMC-derived Runx2 and Runx2-dependent osteogenic differentiation of VSMC in the pathogenesis of vascular calcification. Furthermore, our studies have revealed an intrinsic coupling between calcifying VSMC and the formation of vascular osteoclasts that parallels the bone-remodeling process. Therefore, targeting Runx2 or Runx2 signals in VSMC may represent a novel strategy for prevention and therapytargeting vascular calcification.
Methods
Details of materials and experimental procedures are in the Methods section in the Online Data Supplement.
The smooth muscle specific-Runx2 deficient mice were generated by crossing the Runx2 exon 8 floxed mice (Runx2 f/f ) 25 with the SM22␣-Cre transgenic mice. Characterization of vascular calcification in vivo was performed with mice crossed into ApoE Ϫ/Ϫ background.
Results

Generation of SMC-Specific Runx2 Exon 8 Deletion Mice (Runx2
⌬E8/⌬E8 SMC ) Runx2 ⌬E8/⌬E8 SMC mice were generated by crossing the Runx2 exon 8 floxed mice (Runx2 f/f ) 25 with SM22␣-Cre transgenic mice. Cre-mediated SMC-specific recombination was validated by breeding the SM22␣-Cre with ROSA26 reporter mice (Online Figure I) . Mice from the F1 generation were heterozygous mice with Runx2 ⌬E8/ϩ :Cre ϩ/Ϫ genetic backgrounds. These heterozygous mice were backcrossed with the Runx2 f/f mice to generate Runx2 f/f mice containing the Cre transgene. Deletion of the Runx2 exon 8 was verified by PCR analysis (Online Figure II) .
The homozygous Runx2 ⌬E8/⌬E8 SMC mice were viable with appearance and growth similar to those of the Runx2 f/f littermates. No differences in body weights were identified between Runx2 f/f and Runx2 ⌬E8/⌬E8 SMC mice in both genders (data not shown). Furthermore, we analyzed aortas from Runx2 ⌬E8/⌬E8 SMC and the Runx2 f/f littermates and did not observe any significant differences in aortic smooth muscle cell morphology or gene expression (Online Figure II ).
SMC-Specific Runx2 Deficiency Inhibits VSMC Calcification In Vitro
To determine the effect of Cre-mediated Runx2 deficiency in SMC on vascular calcification, we characterized VSMC isolated from Runx2 ⌬E8/⌬E8 SMC mice and Runx2 f/f littermates. Western blot analysis revealed the expression of a truncated Runx2 protein lacking the exon 8 in VSMC from Runx2 ⌬E8/⌬E8 SMC mice ( Figure 1A ), demonstrating highly Figure 1B , upper panels). In sharp contrast, deletion of the Runx2 exon 8 resulted in inhibition of oxidative stressinduced VSMC calcification ( Figure 1B , lower panels). Furthermore, oxidative stress-induced total calcium content in Runx2 f/f VSMC was blocked by the Runx2 deficiency ( Figure 1C ). Runx2 deficiency concurrently abolished oxidative stress-induced expression of stage-specific osteogenic markers, such as alkaline phosphatase (ALP), type I collagen (Col Ia), and osteocalcin (OC) ( Figure 1D ). On the other hand, oxidative stress-induced decrease in the expression of SMC markers was inhibited by Runx2 deficiency (Online Figure III) . Further characterization determined that the Runx2 truncated protein exhibited markedly reduced transcriptional activity, despite of remaining DNA binding activity (Online Figure IV) . Taken together, these data indicate that Runx2 transcriptional activity is essential for both osteogenic commitment and maturation during VSMC calcification.
SMC-Specific Runx2 Deficiency Inhibits Vascular Calcification In Vivo
To determine the in vivo requirement of Runx2 for vascular calcification, we utilized the atherogenic ApoE Ϫ/Ϫ mouse model. We have previously established that HFD-induced Runx2 expression is associated with increased oxidative stress and atherosclerotic calcification. 22 Figure 2B ). In addition, the presence of the early osteogenic marker, ALP, was also inhibited by the Runx2 deficiency ( Figure 2C ), supporting the role of Runx2 in regulating early and late stages of osteogenic differentiation of the VSMC in vivo.
Furthermore, we determined the direct contribution of the SMC-specific Runx2 deficiency to HFD-induced calcification in the descending aorta. SMC-specific Runx2 deficiency inhibited HFD-induced increase in aortic calcium content measured in the descending arteries ( Figure 2D ). These data demonstrate the importance of SMC-specific Runx2 in the development of vascular calcification in vivo.
SMC-Specific Runx2-Deficiency Inhibits HFD-Induced RANKL Expression and Macrophage Infiltration
We have demonstrated that Runx2 regulates the expression of RANKL via directly binding to the RANKL promoter and that HFD-induced Runx2 is associated with RANKL upregulation and macrophage infiltration in the calcified atherosclerotic lesions in ApoE Ϫ/Ϫ mice. 22 To determine the function of SMC-specific Runx2 in regulating RANKL expression and macrophage infiltration in vivo, the expression of RANKL and the presence of macrophages were compared in the aortic root sections from Runx2 Quantitative analysis determined a significant decrease in RANKL expression and macrophage infiltration in the aortas from Runx2 Figure 3C ). Images taken at a higher magnification further revealed that macrophage infiltration was restricted to the endothelial layer in the Runx2 The effect of the SMC-specific Runx2 deficiency on aortic expression of RANKL and CD68 was further determined in the descending aorta. Quantitative real-time PCR demonstrated that HFD induced aortic expression of RANKL and CD68 in aortas from Runx2 f/f :ApoE Ϫ/Ϫ mice was significantly inhibited by the SMC-specific Runx2 deficiency in the Runx2 ⌬E8/⌬E8 SMC :ApoE Ϫ/Ϫ mice ( Figure  3D ). Together, these data demonstrate that SMC-derived Runx2 mediates macrophage infiltration into the calcified lesions.
SMC-Specific Runx2-Deficiency Inhibits the Formation of TRAP-Positive Osteoclast-Like Cells
The presence of TRAP-positive osteoclast-like cells has been identified in close apposition to the RANKL-positive areas in the calcified atherosclerotic lesions of HFD-fed ApoE Ϫ/Ϫ mice. 22 With immunofluorescent staining, we determined HFDinduced RANKL expression in the calcified atherosclerotic lesions of Runx2 
SMC-Specific Runx2 Deficiency Inhibits the Formation of TRAP-Positive Osteoclast-Like Cells in Coculture
We next assessed the functional contribution of Runx2-regulated RANKL in VSMC, and found that oxidative stress-induced RANKL expression was inhibited in the Runx2 ⌬E8/⌬E8 SMC VSMC in vitro ( Figure 5A & B) . Utilizing a coculture system of VSMC with bone marrow macrophages (BMM), we determined the effects of the Runx2 deficiency in VSMC on the differentiation of BMM into TRAP-positive osteoclasts. BMM cocultured with oxidative stress-treated Runx2 f/f VSMC formed multinucleated TRAP-positive cells ( Figure 5C , upper left panels). In contrast, BMM cocultured with oxidative stress-treated Runx2 ⌬E8/⌬E8 SMC VSMC failed to form multinucleated TRAP-positive cells ( Figure 5C , upper right panels). The defect was restored by addition of soluble RANKL (25 ng/mL) ( Figure 5C , lower panels). These data demonstrate a direct effect of Runx2-mediated RANKL expression by VSMC on the formation of osteoclast-like cells.
Discussion
Emerging studies have supported the finding that vascular calcification is an active cell-driven process characterized by the acquisition of osteogenic phenotype of vascular cells during atherosclerotic development. [1] [2] [3] [4] [5] However, the precise vascular cell type and the molecular mechanisms underlying osteogenic differentiation of vascular cells during atherosclerosis remain undefined. Studies from our group and others have shown that Runx2 is involved in osteogenic differentiation and calcification of VSMC in vitro and that the upregulation of Runx2 is associated with arterial calcification in human and mouse models. 4, 7, 14 But the regulation and contribution of transdifferentiation of VSMC by Runx2 in the pathogenesis of vascular calcification in vivo is unknown. To elucidate the in vivo function of Runx2 in regulating calcification, we generated SMC-specific Runx2 exon 8 deletion mice in ApoE Ϫ/Ϫ background, and demonstrated that SMCspecific Runx2 deficiency inhibits HFD-induced vascular calcification. Our study has provided definitive evidence that osteogenic differentiation of VSMC contributes directly to the pathogenesis of atherosclerotic calcification, and that SMC-derived Runx2 is essential in regulating vascular calcification in vivo.
The SMC-specific Runx2 deficiency did not affect basal vascular smooth muscle phenotype, since the gross anatomy of vessel walls and SMC marker gene expression was similar in control and Runx2 deficiency mice (Online Figure IIB) . This observation is consistent with the finding that Runx2 global knockout mice appear to have a normal cardiovascular system. 8, 9 The expression of Runx2 is very low in normal arteries 13, 14 and in isolated VSMC. 7 We found that the Runx2 deficiency did not affect the basal expression of SMC marker genes, including SMA and SM22␣ (Online Figure III) , which is consistent with our previous observation that Runx2 knockdown by shRNA in VSMC does not result in a compensatory increase in expression of smooth muscle marker genes. 7 In contrast, the impact of the Runx2 deficiency on oxidative stress-induced expression of SMC marker genes is dramatic, as the decrease in expression of the SMC markers under the oxidative stress condition was significantly inhibited in Runx2-deficient VSMC (Online Figure III) . The molecular mechanisms underlying Runx2-regulated expression of SMC markers under oxidative stress might be attributed to its interaction with the key SMC regulators, myocardin and serum response factor (SRF). Overexpression of Runx2 in C3H10T1/2 mesenchymal cells was found to directly interact with SRF and disrupt the formation of myocardin/SRF complex, which in turn repressed myocardin-induced expression of the SMC marker genes. 26 Accordingly, in addition to a direct inhibition of myocardin by oxidative stress, 7 upregulation of Runx2 by oxidative stress (in vitro and in vivo) during vascular calcification may interrupt the formation of the SRF/myocardin complex, and thus contribute to the decreased expression of the SMC gene markers. Therefore, in the Runx2-deficient VSMC, oxidative stress-induced repression of SMC markers was inhibited. Our finding of an inverse correlation of the expression of Runx2 and SMC markers is consistent with the observations that downregulation of the SMC markers is linked to the upregulation of Runx2 in the calcified media from the mice deficient in Matrix Gla protein, a well-studied calcification mouse model. 27, 28 Our studies demonstrate a definitive role of SMC-derived Runx2 in regulating SMC markers and VSMC dedifferentiation under oxidative stress conditions. The inverse correlation of the expression of Runx2 and SMC markers under oxidative stress conditions is consistent with the vascular calcification phenotype we observed in the Runx2-deficient VSMC, supporting a functional contribution of Runx2 to vascular calcification under pathological conditions, such as oxidative stress. Oxidative stress-induced calcification was significantly inhibited in VSMC from Runx2 ⌬E8/⌬E8 SMC mice, despite the presence of the truncated Runx2 protein (Figure 1) . The truncated Runx2 protein contains intact DNA-binding runt homology, nuclear localization signal, and a partial transactivation domain, and thus maintains its DNA binding activity (Online Figure IV) . However, its transcriptional activity was markedly ablated. These results are consistent with previous observation in other cells. 17 In the Runx2 exon 8 -deleted VSMC, oxidative stress-induced upregulation of Runx2-dependent osteogenic marker genes, including OC and ColIa, was also inhibited (Figure 1 ), further demonstrating that oxidative stress induces VSMC calcification via a Runx2-dependent pathway in vitro. 7 These in vitro results are consistent with in vivo observations that SMC-specific Runx2 deficiency blocked HFD-induced vascular calcification in atherosclerotic lesions ( Figure 2 ). Of note, some Alizarin Red-positive punctate calcified nodules were identified in the aortic sections from Runx2 ⌬/⌬ :ApoE Ϫ/Ϫ mice ( Figure 4A , indicated by arrows), which may be explained by the residual activity of the truncated Runx2 in VSMC or Runx2-independent alternative osteogenic pathways. Nevertheless, we also found that the Runx2 deficiency inhibited oxidative stress-induced expression of osterix and Msx2 in VSMC (data not shown), suggesting a key role of Runx2 in regulating multiple signals that contribute to oxidative stress-induced osteogenic differentiation of VSMC.
The observation of the function of the Runx2 exon 8 in regulating VSMC calcification is consistent with previous findings that the Runx2 exon 8 is essential for commitment and progression of the osteoblast and chondrocytes phenotype, 18, 25, 29 and the Runx2 exon 8 truncation results in complete absence of bone formation and embryonic lethality. 18 These in vitro studies suggest that the Runx2 exon 8 is required for vascular calcification in vivo via directly regulating osteogenic differentiation of VSMC. In addition to a direct effect on promoting osteogenic differentiation of VSMC, we have determined that Runx2 mediates oxidative stress-induced expression of RANKL in VSMC by direct binding to the RANKL promoter. 22 RANKL has been reported to be upregulated in atherosclerotic lesions, calcified vessels, and valves. 30 -32 In ApoE Ϫ/Ϫ mice, we have found that HFD induces the expression of RANKL, which is associated with increased expression of Runx2 in the calcified lesions. 22 The present studies further determined that HFD-induced RANKL expression was inhibited in the Runx2-deficient mice (Figure 3) , demonstrating a direct regulation of RANKL by Runx2 in vivo. It was proposed that RANKL may be a procalcification molecule during the development of atherosclerosis. 33 However, inhibition of RANKL per se does not directly inhibit the calcification process, since VSMC from RANKL knockout mice still undergo calcification in response to oxidative stress. 22 In addition, recombinant RANKL protein does not directly promote calcification of mouse primary VSMC in culture. 22 Our studies suggest that Runx2-regulated RANKL expression in VSMC promotes macrophage infiltration into the calcified atherosclerotic lesions. Monocyte/macrophage recruitment plays a critical role in the pathogenesis of atherosclerosis. 23, 24 In the aortas of the Runx2-deficient mice, macrophage infiltration was blocked, and the majority of macrophages were retained in the endothelium layer ( Figure  3 ). The accumulation of macrophages in the arterial wall follows adhesion of circulating monocytes to the endothelium. Once the firm adhesion is established, monocytes transmigrate across the endothelium into the intima along a chemotactic gradient secreted by endothelial cells and SMC. 34 The blockage of macrophage infiltration into the (neo) intima SMC layer in the Runx2-deficient mice ( Figure  3) suggests inhibition of production of SMC-derived chemoattractants. We have previously demonstrated that SMCderived RANKL promotes macrophage migration in vitro, 22 a finding similar to the observation that soluble RANKL protein exhibits chemotactic properties toward monocytes/ macrophages. 35, 36 Therefore, inhibition of HFD-induced expression of RANKL in the Runx2-deficient VSMC directly contributes to impaired macrophage infiltration in the (neo) intimal areas (Figure 3 ). Other chemokines have also been reported to promote macrophage infiltration. A decrease in monocytes/macrophages in arterial walls has been found in mice deficient in monocyte chemoattractant protein-1 (MCP-1) or its primary receptor in vivo, CCR2. 37, 38 RANKL can induce the migration of MonoMac-6 monocytic cells as well as peripheral blood mononuclear cells in a dosedependent manner with an efficacy similar to that of MCP-1. 35 In addition, RANKL induces the expression of MCP-1, which contributes to its effect on macrophage recruitment. 39 Here we found that inhibition of RANKL was associated with decreased expression of MCP-1 and CCR2 in the aortas of Runx2-deficient mice (Online Figure V) . The expression of MCP-1 has been found in neointimal VSMC and intimal macrophages in atherosclerotic lesions of ApoE Ϫ/Ϫ mice. 40 It is likely that SMC-derived RANKL directly regulates MCP-1/CCR2 to induce macrophage infiltration further into the (neo) intimal/medial layers after initial transendothelial migration of macrophages into the subendothelium. Alternatively, Runx2-upregulated RANKL may work in concert with MCP-1/CCR2 to mediate microphage infiltration. Taken together, our data support the role of SMC-derived Runx2 in regulating the expression of these chemo/cytokines that are key to the interplay between VSMC and macrophages.
As a key regulator for osteoclast formation, the major function of RANKL, highly expressed in lymphoid tissues and trabecular bone, is to promote development of multinucleated bone-resorptive osteoclasts from monocytic precursors. 41 Therefore, upregulation of RANKL in VSMC during calcification may contribute to the formation of TRAPpositive multinucleated osteoclast-like cells, which have been observed in close apposition to the mineralized bone-like structures within atherosclerotic plaques of human 42 and mouse arteries. 43 We have previously determined in vitro that SMC-derived RANKL promotes differentiation of macro-phages into TRAP-positive multinucleated osteoclast-like cells in a coculture of VSMC and bone marrow-derived macrophages. 22 The present studies demonstrated that Runx2-upregulted RANKL in VSMC is important for the formation of TRAP-positive osteoclast-like cells in the calcified lesions in vivo. The type(s) of macrophages that develop into osteoclast-like cells is not clear, considering the heterogeneity of the macrophages identified in the atherosclerotic lesions. 44 Runx2-upregulated RANKL expression by VSMC appears to regulate the formation of osteoclast-like cells in vivo and in vitro (Figures 4 and 5) . This is consistent with the finding in the skeleton that the Runx2 deficiency blocks bone formation by inhibiting osteoblast formation, as well as osteoclastogenesis via inhibiting production of RANKL by osteoblasts. 45 Blocking RANKL-using denosumab, a human monoclonal antibody against RANKL, inhibits glucocorticoid-induced osteoporosis as well as vascular calcium deposition in human RANKL knockin mice. 46 Similarly, mice deficient in osteoprotegerin, a soluble decoy receptor for RANKL, exhibit accelerated vascular calcification and increased osteoclast-like cells in the calcified lesions. 19 ,47 Since we have found that VSMC from the RANKL-deficient mice still undergo calcification, the direct function of RANKL in regulating vascular calcification may be attributed to its effects on osteoclastogenesis. The precise function of the osteoclast-like cells found in the vicinity of calcified areas is not clear. We found that the TRAP-positive area was positively correlated with the extent of vascular calcification (Figure 4) , suggesting a coupling between calcifying/calcified VSMC with vascular osteoclasts in regulating vascular calcification, as seen in the interplay of osteoblasts and osteoclasts in regulating bone homeostasis. Our studies have demonstrated the function of VSMC-expressed Runx2 is important in regulating the expression of many factors, including RANKL, which are key to the interplay between VSMC and macrophages that contribute to the pathogenesis of vascular calcification and atherosclerosis.
In conclusion, with a novel SMC-specific Runx2 knockout mouse model, we have demonstrated an important role of osteogenic differentiation of VSMC in the pathogenesis of vascular calcification and determined an essential role of Runx2 in promoting VSMC calcification in vivo. Furthermore, our studies have revealed that Runx2-regulated expression of RANKL in VSMC is crucial in promoting macrophage infiltration into the neointima, as well as osteoclastic differentiation of macrophages in the calcified atherosclerotic lesions ( Figure 6 ). These results support the concept that SMC-derived Runx2 promotes atherosclerotic calcification by coupling the calcification of VSMC and the formation of vascular osteoclasts. Therefore, targeting Runx2 or Runx2-regulating signals in VSMC may represent a novel strategy for prevention and therapy of vascular calcification. . 
Novelty and Significance
What Is Known?
• Atherosclerotic calcification reflects an osteochondrogenic transformation of vascular cells, which is associated with increased expression of bone-related markers.
• Runx2 regulates calcification of vascular smooth muscle cells (VSMC) in vitro.
• TRAP-positive osteoclast-like cells are present in calcified atherosclerotic plaques, in the vicinity of ectopic mineralization sites.
• Increased RANKL, a key regulator for osteoclast differentiation, is associated with vascular calcification.
What New Information Does This Article Contribute?
• Osteogenic differentiation of VSMC plays an important role in the pathogenesis of vascular calcification in vivo.
• Smooth muscle cell-derived Runx2 regulates osteogenic differentiation of VSMC and atherosclerotic calcification in vivo.
• The Runx2 exon 8 is essential for its function to regulate osteogenic differentiation of VSMC; however, deletion of the Runx2 exon 8 does not affect basal SMC markers.
• SMC-specific Runx2 deficiency inhibits high-fat diet inducedexpression of RANKL in calcified atherosclerotic lesions, and blocks the formation of TRAP-positive osteoclast-like cells and infiltration of CD68-positive macrophages.
• The amount of TRAP-positive area in the calcified atherosclerotic lesions is positively correlated with the extent of calcification, suggesting that the formation of osteoclast-like cells is coupled with the development of vascular calcification in vivo.
• Runx2 deficiency inhibits RANKL production by VSMC, which abolishes osteoclastic differentiation of bone marrow-derived macrophages in a coculture system.
Atherosclerotic calcification reflects an osteochondrogenic transformation of vascular cells. We have previously identified that the osteogenic transcription factor, Runx2, is essential for oxidative stress-induced VSMC calcification in vitro. The present study demonstrates, for the first time, the importance of osteogenic differentiation of VSMC in the pathogenesis of vascular calcification in vivo. With a novel SMC-specific knockout mouse model, we have determined a critical role of SMC-derived Runx2 and Runx2-dependent osteogenic differentiation of VSMC in regulating vascular calcification in vivo. Our studies reveal intrinsic coupling between calcifying VSMC and the formation of vascular osteoclasts in the calcified atherosclerotic lesions, which parallels the bone remodeling process.
